- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01337453
Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy
Botulinum toxin (BoNT) has become a revolutionary treatment for many neurological, autonomic, gastrointestinal, genitourinary, and cosmetic disorders. The use of this treatment requires expertise in dosage calculations and application technique to avoid potential side effects. Most adverse events (AEs) related to BoNT are local and related to its mechanism of action, i.e., paralysis of unwanted muscles. However, systemic AEs may also be observed. Flu-like symptoms (FLS) are well recognized AEs in patients treated with BoNT; however there is a paucity of information regarding the frequency, clinical impact, and associated risk factors of this particular complication.
Between December 1989 and May 2003, 1,437 reports of BoNT-related AEs were registered at the Food and Drug Administration (FDA). FLS were reported in 4.6% of serious, and 3.2% of non-serious side effects.
In this study, the investigators aim to assess prospectively the frequency, clinical characteristics, and risk factors for development of FLS in a group of patients affected with diverse movement disorders and treated with BoNT type A at the Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC) of Baylor College of Medicine (BCM). The investigators will also assess biomarker of inflammatory response in those patients who develop FLS after treatment with BoNT.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine, Dept. of Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- The investigators plan to study 300 consecutive patients treated with BoNT at the Parkinson Disease center and Movement Disorders Clinic (PDCMDC) of Baylor College of Medicine.
- The investigators will invite patients to participate in the study during an eight-month period that includes two cycles of BoNT injections. All patients within this period will be invited to take part in the clinical study. This will include patients who have never been injected in our clinic and are considered as "new" patients; and patients who are followed on a regular basis in our clinic and are considered as "established" patients.
Description
Inclusion Criteria:
- Patients with any movement disorder: dystonia, tremor, tics, myoclonus or tardive dyskinesias and treated with botulinum toxin type A (Botox or Dysport) to type B (Myobloc)
- Patients who will be injected in at least two consecutive visits in our clinic, three months apart.
- We will invite patients who are regularly treated in our clinic "established patients" and those who will be treated for the first time "new patients".
- Patients who are willing to complete with the study requirements.
- Patients who deny the blood sample will be included for the symptoms and risk factors analysis.
- Patients who give written informed consent.
Exclusion Criteria:
- Patients who will only be injected with BoNT once in our clinic at BCM.
- Patients who deny participating in the clinical survey.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Flu-like symtoms, incidence
The frequency of FLS will be estimated by number of patients and number of Botox treatments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The frequency of FLS will be estimated by number of patients and number of Botox treatments
Time Frame: Eight months or 2 treatment cycles
|
The frequency of FLS will be estimated by number of patients and number of Botox treatments
|
Eight months or 2 treatment cycles
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- H-27678
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flu-like Symptoms
-
Aarogyam UKCompletedFlu Like Symptom | Flu Like IllnessUnited Kingdom
-
Avila HerbalsUnknownFlu-like SymptomsUnited States
-
Aarogyam UKCompleted
-
Franklin Health ResearchArtemis International; IPRONARecruitingCOVID-19 | Flu | Cold | Upper Respiratory Tract Infection | Flu Like IllnessUnited States
-
Hospital de Clinicas de Porto AlegreUnknownCommon Cold | Flu-like SyndromeBrazil
-
University of PennsylvaniaNational Institute on Aging (NIA); University of WashingtonActive, not recruitingFlu | Behavior, Health | Flu VaccinationUnited States
-
Professor Adrian CovicFalcon Trading Iasi; Romanian Academy of Medical SciencesUnknownCOVID-19 | Pneumonia, Viral | Pneumonia, Ventilator-Associated | Flu Symptom | Flu Like Illness | Influenza With Pneumonia | Pneumonia, Interstitial | Pneumonia AtypicalItaly, Romania, United Kingdom
-
The Cooper Health SystemWon Sook Chung FoundationCompletedRespiratory Tract Infections | Covid19 | Flu Like IllnessUnited States
-
Kemin Foods LCKGK Science Inc.CompletedStress | Flu | Cold | Flu Symptom | Cold Symptom | Gastrointestinal Tolerance | SupplementCanada
-
Mahidol UniversityCompleted